Public Employees Retirement Association of Colorado increased its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 85.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,189 shares of the biopharmaceutical company’s stock after purchasing an additional 1,010 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Loxo Oncology were worth $374,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of Loxo Oncology by 15.5% in the 2nd quarter. BlackRock Inc. now owns 2,095,164 shares of the biopharmaceutical company’s stock valued at $363,468,000 after buying an additional 280,475 shares during the last quarter. OppenheimerFunds Inc. boosted its holdings in shares of Loxo Oncology by 6.4% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,115,675 shares of the biopharmaceutical company’s stock valued at $193,547,000 after buying an additional 66,794 shares during the last quarter. Northern Trust Corp lifted its holdings in Loxo Oncology by 14.0% during the 2nd quarter. Northern Trust Corp now owns 325,357 shares of the biopharmaceutical company’s stock valued at $56,442,000 after purchasing an additional 39,846 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Loxo Oncology during the 2nd quarter valued at $55,115,000. Finally, Voya Investment Management LLC lifted its holdings in Loxo Oncology by 0.4% during the 2nd quarter. Voya Investment Management LLC now owns 186,422 shares of the biopharmaceutical company’s stock valued at $32,340,000 after purchasing an additional 661 shares during the last quarter. 97.41% of the stock is owned by institutional investors.
LOXO stock opened at $152.66 on Thursday. Loxo Oncology Inc has a fifty-two week low of $71.45 and a fifty-two week high of $208.95.
Several equities research analysts have issued reports on the company. BidaskClub raised Loxo Oncology from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 7th. Cann reaffirmed an “average” rating and set a $202.00 price target (up previously from $122.00) on shares of Loxo Oncology in a report on Thursday, July 12th. Zacks Investment Research downgraded Loxo Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. Piper Jaffray Companies set a $200.00 price target on Loxo Oncology and gave the company a “buy” rating in a report on Wednesday, September 26th. Finally, Goldman Sachs Group assumed coverage on Loxo Oncology in a report on Monday, September 17th. They set a “neutral” rating and a $165.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $188.75.
In other Loxo Oncology news, CEO Joshua H. Bilenker sold 20,000 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $159.41, for a total transaction of $3,188,200.00. Following the transaction, the chief executive officer now owns 145,407 shares in the company, valued at approximately $23,179,329.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jennifer Burstein sold 2,500 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $159.24, for a total value of $398,100.00. Following the transaction, the vice president now owns 1,250 shares in the company, valued at approximately $199,050. The disclosure for this sale can be found here. Insiders have sold a total of 102,500 shares of company stock worth $16,798,550 in the last quarter. Company insiders own 17.10% of the company’s stock.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Recommended Story: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.